Skip to main content
Premium Trial:

Request an Annual Quote

David Hoffmeister, Kate Gilbert, Emily Winn-Deen, Sam Rua, and Laurie Keating


David Hoffmeister has become CFO and senior vice president of Invitrogen, succeeding Eric Winzer, the Carlsbad, Calif.-based company said this week. He joins the company from McKinsey, where he was a senior partner. Winzer will remain part of the Invitrogen executive team.

Kate Gilbert has been promoted to director of marketing of Ciphergen Biosystems. She replaces Dick Rubin, who left the company in August. Gilbert was previously consumables product manager at Ciphergen.

Emily Winn-Deen has joined Cepheid of Sunnyvale, Calif., as vice president of strategic planning and business development, the company said last month. Most recently, she led the genomics business group at Roche Molecular Systems in Pleasanton, Calif. In the past, she held appointments at Applied Biosystems, Oncor, and Celera Genomics. Winn-Deen holds a PhD in chemistry from Boston University and a BS in chemistry from Lehigh University.

Sam Rua has become director of regulatory affairs and quality assurance of Third Wave Technologies, the Madison, Wis.-based company said this week. Rua, 44, joins the company from Ventana Medical Systems, where he was director of regulatory affairs. He holds a bachelor’s degree in microbiology from the University of Arizona.

Laurie Keating has become senior vice president, general counsel, and secretary of Millennium Pharmaceuticals, the Cambridge, Mass.-based company said last week. Most recently, she was executive vice president of operations and finance and a member of the board of directors of Hydra Biosciences.

Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.